A Study of the Role of Elevated Free Fatty Acids in Blood Plasma for the Regulation of Muscle Protein Manufacture
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Scottsdale/Phoenix, Arizona: 15-004784
Sponsor Protocol Number: 15-004784
About this study
The purpose of this study is to determine the effects of increased free fatty acid concentrations in blood plasma, on the metabolism of muscle proteins.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria
- Body mass index (BMI) 19-30 kg/m2
- Age 18-45 years
- Availability of transportation
- Ability to sign informed consent form
Exclusion Criteria
- Medication or supplements (i.e. amino acids, protein) known to affect protein metabolism
- Presence of acute illness
- History of liver disease
- Uncontrolled metabolic disease, including renal disease
- Atrial fibrillation, history of syncope, limiting or unstable angina, or congestive heart failure
- Chronically elevated blood pressure with systolic, >140 mmHg or diastolic >100 mmHg
- Cardiac pacemaker or other medical device implanted in the body
- ECG documented abnormalities such as >0.2 mV horizontal or downsloping ST-segment depression, frequent arrhythmias of >10 premature ventricular contractions/min, or valvular disease
- Low hemoglobin or hematocrit with 2-h plasma glucose >200 mg/dl in the OGTT
- Current participation in a weight-loss regimen, including extreme dietary practices
- Smoking
- Use of anabolic steroids or corticosteroids within 3 months
- Any other condition or event considered exclusionary by the PI and the study physician
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Scottsdale/Phoenix, Ariz.
Mayo Clinic principal investigator Lori Roust, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available